The Wegovy pill for men: what to expect week by week, from the starting dose to maintenance

The Wegovy pill (oral semaglutide) starts at 1.5 mg once a day for one month. The dose then steps up to 4 mg, 9 mg and 25 mg. Each level lasts at least one month, and the 25 mg tablet is the maintenance dose. [1]

The tablet has one rule of its own: an empty stomach and a 30-minute wait. Side effects cluster around each dose step and usually ease with time. That pattern is expected.

This article sets out what the UK licence, the OASIS 4 trial and the medicines regulator say about each stage. It is a reference for men starting the tablet, so you can read your own experience against what the evidence calls normal.

How does the Wegovy pill dose build up?

Four steps, one month each at minimum. The licence sets the starting dose at 1.5 mg once daily. After one month the dose rises to 4 mg, then 9 mg, then 25 mg. [1]

Stepping the dose up in stages is called titration. The table shows the schedule from the UK Summary of Product Characteristics (the licence document for the medicine) and the patient leaflet. [1] [2]

Stage	Dose	What the licence says
Month 1 (weeks 1 to 4)	1.5 mg once daily	The starting dose
Month 2 (weeks 5 to 8)	4 mg once daily	First escalation step
Month 3 (weeks 9 to 12)	9 mg once daily	Second escalation step
Month 4 onwards (week 13)	25 mg once daily	The maintenance dose and the maximum

The licence allows a pause. If needed, the dose can stay at the previous level for longer. [1] Your clinician sets the pace from how you tolerate each step.

One tablet a day is the rule at every step. Never take two tablets to reach a higher dose. [1]

How do you take the tablet?

On an empty stomach, after a fast of at least 8 hours. Swallow the tablet whole with a sip of water, up to 120 mL, which is about half a glass. [1]

Then wait at least 30 minutes before you eat, drink or take any other oral medicine. Waiting less than 30 minutes lowers the amount of semaglutide your body absorbs. [1]

The routine matters more with this medicine than with most. Only about 1% to 2% of an oral dose is absorbed, and the amount varies. [1] If your response is lower than expected, the licence tells clinicians to bear variable absorption in mind. [1]

• Do not split, crush or chew the tablet. [1]
• Food or a large volume of water with the tablet reduces absorption. [1]
• Other tablets taken at the same time reduce absorption too. Take them after the 30-minute wait. [1]
• The licence sets no clock time. The 8-hour fast and the 30-minute wait are the rules. [1]

If you miss a dose, skip it. Take the next dose the following day. [1]

What happens in weeks 1 to 4 on 1.5 mg?

The first month is about tolerability. The 1.5 mg dose is the starting dose, not the maintenance dose. [1]

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a gut hormone that regulates appetite and calorie intake. A receptor agonist is a medicine that acts on the same receptors as the hormone. [1]

The GLP-1 receptor is present in several areas of the brain involved in appetite regulation. The medicine also slightly delays stomach emptying in the first part of digestion after a meal. [1] Reduced appetite is the mechanism, not a side effect.

Side effects in the first weeks

Digestive side effects are the most common. In the trials these were very common, which means more than 1 in 10 people, and mainly seen during dose escalation: [1]

• nausea
• vomiting
• diarrhoea
• constipation
• indigestion
• abdominal pain

Headache and fatigue were also very common and mainly seen during dose escalation. [1] Dizziness was common, mainly in the same period. [1]

The patient leaflet says these effects usually go away over time. [2] They can still cause dehydration. Drink plenty of fluids throughout treatment. [1] [6]

What changes in weeks 5 to 12 as the dose rises?

Month 2 brings the 4 mg dose and month 3 the 9 mg dose. [2] Each step can bring the digestive effects back for a while. In the trial, they were most frequently reported during dose escalation. [1]

The OASIS 4 trial reports the figures over its full 64 weeks against a placebo, an inactive comparison tablet. [1]

• Nausea: 46.6% on the tablet, 18.6% on placebo.
• Vomiting: 30.9% against 5.9%.
• Diarrhoea: 17.6% against 8.8%.
• Constipation: 20.1% against 9.8%, and of longer duration than the others.

Most events were mild to moderate and short in duration. [1] The regulator notes they can persist for several days. [6] In the trial, 3.4% of people stopped the tablet because of a digestive event. [1]

If a step is hard going, the licence allows the dose to stay at the previous level. [1] Tell your clinician rather than pushing through.

What does maintenance on 25 mg look like from week 13?

From month 4 the dose is 25 mg once daily, the maintenance dose. [2] Semaglutide has a half-life of about one week, the time for the blood level to fall by half. A steady level in the body is reached after 4 to 5 weeks of daily dosing. [1]

At steady state, the 25 mg tablet gives a blood level comparable to the 2.4 mg Wegovy injection. [1]

What the trial found

OASIS 4 followed 307 adults without diabetes for 64 weeks: 12 weeks of dose escalation, then 52 weeks on 25 mg. [3] [4] Weight loss occurred early and continued throughout the trial. [1]

• Mean weight change at 64 weeks, counting everyone randomised: 13.6% on the tablet and 2.2% on placebo. [1] [3]
• A second estimate, assuming everyone stayed on treatment and took no other weight-loss therapy: 16.6% and 2.8%. [1]
• Lost 5% or more: 76.3% on the tablet against 30.5% on placebo. Lost 10% or more: 59.8% against 14.1%. [1]
• Waist circumference fell by 12.2 cm against 2.8 cm. [1]

Average trial results are not a prediction of individual results.

Two points matter for men reading those figures. Only 65 of the 307 participants were men. [4] The licence records relatively greater weight loss in women. Neither the licence nor the trial report gives a male-only figure. [1]

The published results are the 64-week figures, so this article gives no week-by-week weight curve.

Less common effects to know about

• Hair loss: 6.4% on the tablet against 2.0% on placebo, all mild or moderate, and more frequent with larger weight loss. [1]
• Gallstones: 2.5% against 1%. [1]
• Altered skin sensation, such as tingling: 4.9% on the tablet and none on placebo. [1]
• Acute pancreatitis is uncommon, which means between 1 in 1,000 and 1 in 100 people. None occurred on the tablet in OASIS 4. [1]
• Low blood sugar is common only in people with type 2 diabetes, and uncommon otherwise. [1]

When should you contact your clinician?

Seek urgent medical attention for severe, persistent abdominal pain that may spread to your back. This can be a sign of acute pancreatitis. [7] Seek urgent help too for any sudden loss of vision, including partial loss. [1]

Contact your clinician promptly for:

• vomiting or diarrhoea that stops you keeping fluids down, because dehydration can harm the kidneys [1]
• signs of low blood sugar, if you have type 2 diabetes and also take insulin or a sulfonylurea (a type of diabetes tablet) [1]
• any planned operation or procedure under general anaesthetic or deep sedation, so the team knows you take semaglutide [1]
• any other medicine you take, including levothyroxine and warfarin, because the licence asks for monitoring with both [1]
• any new or unusual symptom that worries you

Only use medicine from a registered prescriber and an authorised pharmacy. The regulator warns against unregulated sellers and reports falsified medicines. [6] [8]

Is the Wegovy pill available on the NHS?

Not at present. The regulator said at approval that the tablet is not available through the NHS and that NHS decisions follow a NICE evaluation. [5]

NICE, the National Institute for Health and Care Excellence, discontinued its appraisal of the tablet in May 2025. The company had said it would not submit evidence. [9] No appraisal of the tablet has been published since.

The injection is different. NICE recommends it for NHS use only within specialist weight management services, for a maximum of 2 years, with BMI and weight-related condition criteria. [9] BMI is body mass index, your weight against your height.

How does HeMed fit in?

HeMed starts with a blood test. We measure 10 metabolic markers across four systems from a needle-free blood test at home.

A clinician reviews your blood test first. If they approve treatment, we deliver it the next working day, discreetly packaged, with delivery included in your plan.

Your dose moves on how you are doing, not on a calendar. If side effects are still settling on a lower dose, your clinician can hold that dose before any increase, as the licence allows. [1] No step comes sooner than the licence minimum of one month. [1]

A weekly in-app check-in, reviewed by clinicians, so your plan can be adjusted when it needs to be. A retest every 6 months shows what’s actually changing.

The Wegovy pill is a prescription medicine for weight management. Whether it’s right for you is a clinical decision, made from your health information and your baseline blood test.

Frequently asked questions

When do appetite changes start?

Appetite regulation is how the medicine works, and the licence records that weight loss began early in the trial and continued throughout. The published results are the 64-week figures, so no verified week-by-week curve exists. The dose builds over 3 months, and a steady blood level takes 4 to 5 weeks of daily dosing.

When do side effects settle?

Digestive effects were most frequently reported during dose escalation and were mostly mild to moderate and short in duration. The patient leaflet says they usually go away over time, and the regulator says they can persist for several days. Constipation lasted longer than the other effects in the trial.

Why do I have to wait 30 minutes before eating?

Very little of an oral semaglutide dose is absorbed, about 1% to 2%, and food, drink or other tablets in the stomach reduce it further. The licence requires an empty stomach after an 8-hour fast and a sip of water of up to 120 mL. Then comes a 30-minute wait before anything else.

What if I miss a dose?

Skip it and take the next dose the following day. Do not take two tablets in one day. If you are unsure, contact your clinician.

Can I move from the Wegovy injection to the tablet?

The licence says people on the 2.4 mg Wegovy injection can move to the 25 mg tablet, starting one week after the last injection. It also warns that the effect of switching is hard to predict, because the tablet's absorption varies more. That makes it a decision for your clinician.

What does NICE say about NHS access?

NICE has not appraised the tablet. Its appraisal was discontinued in May 2025 when the company declined to submit evidence, so the tablet is not available on the NHS.

NICE recommends the injection only within specialist weight management services and for up to 2 years. The criteria are at least one weight-related condition plus a BMI of at least 35. A BMI of 30 to 34.9 qualifies with the criteria for referral to a specialist service.

HeMed provides clinician-led weight management. Treatment is prescription-only and is prescribed only where a clinician decides it is suitable. This page is general health information, not medical advice. If you are worried about symptoms, speak to your GP, or use NHS 111.

Next step: see what the HeMed blood test measures.

Sources (9)

1. Novo Nordisk, Wegovy 25 mg tablets (semaglutide) Summary of Product Characteristics, sections 4.1, 4.2, 4.4, 4.5, 4.7, 4.8, 5.1 and 5.2 (text revised June 2026). electronic medicines compendium. medicines.org.uk/emc/product/102347/smpc. Accessed 13 October 2026.
2. Novo Nordisk, Wegovy tablets Patient Information Leaflet, sections 3 and 4 (last updated 16 June 2026). electronic medicines compendium. medicines.org.uk/emc/product/102347/pil. Accessed 13 October 2026.
3. Wharton S, Lingvay I, Bogdanski P and colleagues. "Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity" (OASIS 4). New England Journal of Medicine 2025;393(11):1077 to 1087. doi.org/10.1056/NEJMoa2500969. Accessed 13 October 2026.
4. ClinicalTrials.gov, "A Research Study to See How Semaglutide Helps People With Excess Weight Lose Weight" (OASIS 4), NCT05564117: arm descriptions, participant flow and baseline characteristics, results first posted 25 February 2026. clinicaltrials.gov/study/NCT05564117. Accessed 13 October 2026.
5. MHRA, "First GLP-1 tablet for weight loss approved in the UK", 11 June 2026. gov.uk/government/news. Accessed 13 October 2026.
6. MHRA Drug Safety Update, "GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse", 24 October 2024. gov.uk/drug-safety-update. Accessed 13 October 2026.
7. MHRA Drug Safety Update, "GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases", 29 January 2026. gov.uk/drug-safety-update. Accessed 13 October 2026.
8. MHRA, "GLP-1 medicines for weight loss and diabetes: what you need to know", updated 5 February 2026. gov.uk/government/publications. Accessed 13 October 2026.
9. NICE, "Oral semaglutide for managing overweight and obesity [ID6188]", GID-TA11149, discontinued 12 May 2025, nice.org.uk/guidance/awaiting-development/GID-TA11149; and NICE, "Semaglutide for managing overweight and obesity", TA875, recommendations 1.1 and 1.2 (8 March 2023, updated 4 September 2023), nice.org.uk/guidance/ta875. Accessed 13 October 2026.

Numbered markers in the page text link to these entries. Statistics describe populations, not any one person’s results.